Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 618-625

  Vale, Claire L ^a   Tierney, Jayne F ^a   Fisher, David ^a   Adams, Richard A ^b   Kaplan, Richard ^a   Maughan, Timothy S ^c   Parmar, Mahesh K B ^a   Meade, Angela M ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti EGFR therapy; Colorectal cancer; Meta analysis; Systematic review

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DRUG INFUSION; GENE MUTATION; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MUTANT; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MUTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84861656612     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.11.002     Document Type: Review

References (34)

1. Linardou H., Dahabreh I.J., Kanaloupiti D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9(10):962-972.
2. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27(12):2091-2096.
3. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011; doi: 10.1007/s00384-011-1149-0.
4. Tveit K., Guren T., Glimelius B., et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314) by the Nordic Colorectal Cancer Biomodulation Group. Ann Oncol 2010, 21(8(supplement)):LBA20.
5. Bokemeyer C., Kohne C.H., Rougier P., Stroh C., Schlichting M., Van Cutsem E. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clini Oncol 2010, 28(15S):3506.
6. Cochrane handbook for systematic reviews of interventions 2008, John Wiley & Sons Ltd., Chichester. J.P.T. Higgins, S.J. Green (Eds.).
7. Parmar M.K.B., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
8. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8(1):16.
9. Williamson P.R., Tudur Smith C., Hutton J.L., Marson A.G. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002, 21:3337-3351.
10. The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphomide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002, 360(9332):505-515.
11. Borner M., Koeberle D., Von Moos R., et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008, 19(7):1288-1292.
12. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(14):2311-2319.
13. Polikoff J., Mitchell E.P., Badarinath S., et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol 2005, 23(16S):3574.
14. Venook A., Niedzwiecki D., Hollis D., et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX)±cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006, 24(18S):3509.
15. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360(6):563-572.
16. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27(5):672-680.
17. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664.
18. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765.
19. Van Cutsem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (MCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008, 26(15S):2.
20. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS stsus and efficacy of first line treatment of patients with metastatic colorectal cancer (MCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008, 26(15S):4000.
21. Douillard J.Y., Siena S., Cassidy J., et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer Suppl 2009, 7(3):6.
22. Maughan T.S., Adams R., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377(9783):2103-2114.
23. Peeters M., Price T., Hotko Y., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(31):4706-4713.
24. Diaz-Rubio E., Tabernero J., Gomez-Espana A., et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007, 25(27):4224-4230.
25. Porschen R., Arkenau H.T., Kubicka S., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007, 25(27):4217-4223.
26. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25(30):4779-4786.
27. Arkenau H.T., Arnold D., Cassidy J., et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008, 26(36):5910-5917.
28. Cao Y., Liao C., Tan A., Liu L., Mo Z., Gao F. Capecitabine plus oxaliplatin versus fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal cancer: meta-analysis of six randomised trials. Colorectal Dis 2010, 12(1):16-23.
29. Comella P., Massidda B., Filippelli G., et al. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol 2009, 135(2):217-226.
30. Cassidy J., Clarke S., Diaz-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26(12):2006-2012.
31. Martoni A.A., Pinto C., Di Fabio F., et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer 2006, 42(18):3161-3168.
32. Rothenberg M.L., Cox J.V., Butts C., et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008, 19(10):1720-1726.
33. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007, 5(3):203-220.
34. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762.